Form 4: Xenon Pharmaceuticals CFO Sells Shares After Option Exercises
SEC Form 4 Filing
Xenon Pharmaceuticals' Chief Financial Officer, Sherry Aulin, executed multiple transactions involving the exercise of stock options and subsequent sale of shares on December 18, 2024.
Summary
- Sherry Aulin, the Chief Financial Officer of Xenon Pharmaceuticals, engaged in several transactions on December 18, 2024.
- These transactions included the exercise of stock options to acquire 9,334 shares at $9.44 and 16,000 shares at $11.58.
- Following the option exercises, Aulin sold 7,199 shares at a weighted average price of $41.23 and 11,510 shares at a weighted average price of $41.19.
- The sales were conducted in multiple transactions with prices ranging from $41.19 to $41.20 per share.
- After these transactions, Aulin directly owns 0 common shares and 6,000 stock options.
Sentiment
Score: 5
Explanation: The document reflects standard insider trading activity. While the sale of shares could be seen as slightly negative, it is a common practice and does not necessarily indicate a negative outlook for the company.
Negatives
- The CFO sold a significant number of shares after exercising options, which could be interpreted negatively by some investors.
Risks
- Insider selling, even if planned, can sometimes create negative market sentiment.
Industry Context
This is a routine SEC Form 4 filing, which is common for company insiders who exercise stock options and sell shares. It is a standard practice and does not necessarily indicate a change in the company's outlook.
Comparison to Industry Standards
- Similar transactions are common among executives in publicly traded companies, especially those with stock-based compensation.
- The sale of shares after exercising options is a typical way for executives to realize the value of their compensation.
- The price range of $41.19 to $41.20 per share is within the expected range for a company of this type.
Stakeholder Impact
- The sale of shares by the CFO could have a minor negative impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 12/18/2024 | Date of stock option exercises and share sales by Sherry Aulin. |
| 09/15/2029 | Expiration date of one set of stock options exercised. |
| 03/11/2030 | Expiration date of another set of stock options exercised. |
Keywords
Xenon Pharmaceuticals, insider trading, stock options, share sale, Sherry Aulin, CFO, XENE
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.